Pathogenesis of haemophagocytic lymphohistiocytosis

British Journal of Haematology

Volumn 114, Issue 4, 2001, Pages 761-769

  Arico M ^a   Danesino, C ^a   Pende, D ^a   Moretta, L ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cytotoxicity; Histiocytosis; NK cells; Perforin

Indexed keywords

CD28 ANTIGEN; GRANZYME A; GRANZYME B; INTERLEUKIN 1; INTERLEUKIN 6; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW TRANSPLANTATION; CELL FUNCTION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROPHAGOCYTOSIS; FAMILIAL DISEASE; GENETIC MARKER; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE RESPONSE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANTIGEN-PRESENTING CELLS; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; INFANT; INFANT, NEWBORN; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; PORE FORMING CYTOTOXIC PROTEINS; VIRUS DISEASES;

EID: 0034795745     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02936.x     Document Type: Review

References (86)

1. Familial hemophagocytic lymphohistiocytosis: How late can the onset be?
2. Neuropathology of familial erythrophagocytic lymphohistiocytosis
3. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213
4. Mononuclear cell derangement in familial hemophagocytic lymphohistiocytosis
5. Clinical aspects of Langerhans cell histiocytosis
6. Natural cytotoxicity impairment in familial haemophagocytic lymphohistiocytosis
7. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry
8. Hemophagocytic lymphohistiocytosis in a patient with deletion of 22q11.2
9. The breakpoints of a constitutional inversion of chromosome 9 associated with haemophagocytic lymphohistiocytosis are not linked to the disease gene
10. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene
11. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation
12. Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor
13. Treatment of hemophagocytic lymphohistiocytosis with chemotherapy and bone marrow transplantation: A single-center study of 22 patients
14. Abnormal T-cell phenotype in familial hemophagocytic lymphohistiocytosis
15. Spontaneous NBT reduction by monocytes as a marker of disease activity in children with histiocytosis
16. Six novel mutations in the PRF1 gene in children with hemophagocytic lymphohistiocytosis
17. Expression of bcl-X (L) restores cell survival, but not proliferation of effector differentiation, in CD28-deficient T lymphocytes
18. Granzyme A- and B- deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity
19. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity
20. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: A single-centre experience of 12 patients
21. Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance
22. Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients
23. Familial haemophagocytic reticulosis
24. Histiocytosis syndromes and related disorders of early infancy: A pathologist's perspective
25. Contemporary classification of histiocytic disorders
26. Treatment of four patient with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate and cranial irradiation
27. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis
28. Hemophagocytic syndrome: A misleading complication of visceral leishmaniasis in children. A series of 12 cases
29. Identification of an astrocyte cell population from human brain that expresses perforin, a cytotoxic protein implicated in immune defense
30. Genetic analysis of familial erythrophagocytic lymphohistiocytosis
31. Fragile site on chromosome 2 (q11) in a case of familial lymphohistiocytosis
32. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis
33. Further evidence for genetic heterogeneity in familial hemophagocytic lymphohistiocytosis
34. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis
35. Familial hemophagocytic lymphohistiocytosis macrophages showing immunohistochemical properties of activated macrophages and T-accessory cells
36. Haemophagocytic lymphohistiocytosis associated with constitutional inversion of chromosome 9
37. Cerebromeningeal haemophagocytic lymphohistiocytosis
38. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis
39. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
40. Diagnostic guidelines for hemophagocytic lymphohistiocytosis
41. Familial hemophagocytic lymphohistiocytosis and viral infections
42. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis
43. Primary hemophagocytic lymphohistiocytosis
44. The roles of CD28 and CD40 ligand in T cell activation and tolerance
45. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population
46. Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan
47. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy
48. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors
49. Familial hemophagocytic lymphohistiocytosis
50. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis
51. Clonal and non-clonal karyotypically abnormal cells in haemophagocytic lymphohistiocytosis
52. Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis
53. In vivo natural killer cell activities revealed by natural killer cell-deficient mice
54. Partial albinism with immunodeficiency (Griscelli syndrome)
55. Chromosome abnormalities in familial hemophagocytic lymphohistiocytosis
56. Elevated soluble interleukin-2 receptor in childhood hemophagocytic lymphohistiocytosis
57. Immunodeficiency in familial erythrophagocytic lymphohistiocytosis
58. Partial engraftment of donor bone marrow cells associated with long-term remission of haemophagocytic lymphohistiocytosis
59. Macrophage precursor cells produce perforin and perform Yac-1 lytic activity in response to stimulation with interleukin-2
60. Hepatitis A causing a second episode of virus-associated haemophagocytic lymphohistiocytosis in a patient with Still's disease
61. The molecular basis of natural killer (NK) cell recognition and function
62. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis
63. Human NK-cell receptors
64. Mannnose 6-phosphate/Insulin-like growth factor II receptor is a dath receptor for Granzyme B during cytotoxic T-cell induced apoptosis
65. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping
66. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis
67. Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: Participation of both T cells and NK cells in the killing
68. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells
69. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene
70. Impaired natural killer activity in lymphohistiocytosis syndrome
71. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo
72. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine
73. Virus-associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis
74. Bacteria-associated hemophagocytic syndrome
75. Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis
76. Perforin is a major contributor to NK cell control of tumor metastasis
77. Immunologic dysregulation in a patient with familial hemophagocytic lymphohistiocytosis
78. Cytotoxic T cell responses to intracellular pathogens
79. Reactive hemophagocytic syndrome in children
80. Perforin gene defects in familial hemophagocytic lymphohistiocytosis
81. Perforin, interferon-γ_activities independently control tumor initiation, growth and metastasis
82. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives
83. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease
84. Successful engraftment of unrelated cord blood stem cells for familial erythrophagocytic lymphohistiocytosis
85. Allogeneic bone marrow transplantation for familial erythrophagocytic lymphohistiocytosis with high dose VP16-containing conditioning regimen
86. Biology of natural killer cells